Biggest Threat To CEPI’s Goals Is ‘Not Scientific, But Political’

New York Times: Stopping Pandemics Before They Start
Tina Rosenberg, author and a co-founder of the Solutions Journalism Network

“…Over the next five years, [the Center for Epidemic Preparedness Innovations (CEPI)] aims to develop multiple viable vaccine candidates against three pathogens: Lassa fever, Nipah, and Middle East Respiratory Syndrome. … One of CEPI’s goals is to create simpler, more agile structures for approvals. CEPI’s second goal is to create a vaccine delivery system that can be quickly adapted to stem new pathogens … CEPI also aims to achieve full approval and manufacture for the Ebola vaccine … CEPI has no manufacturing facilities. It will, instead, finance research and development at pharmaceutical or biotech companies. CEPI will require its awardees to sell vaccines to the poorest and lower-middle-income countries (more likely, to donors who will buy vaccine for them) at the lowest possible price. … CEPI’s value may go beyond the success of any single vaccine. The organization’s ability to streamline a vaccine process will likely matter more than any new product, said Seth Berkley, the chief executive of GAVI, the Vaccine Alliance … The biggest threat to this mission is not scientific, but political — our short attention span…” (6/27).

The KFF Daily Global Health Policy Report summarized news and information on global health policy from hundreds of sources, from May 2009 through December 2020. All summaries are archived and available via search.

KFF Headquarters: 185 Berry St., Suite 2000, San Francisco, CA 94107 | Phone 650-854-9400
Washington Offices and Barbara Jordan Conference Center: 1330 G Street, NW, Washington, DC 20005 | Phone 202-347-5270 | Email Alerts: | |

The independent source for health policy research, polling, and news, KFF is a nonprofit organization based in San Francisco, California.